Boston Scientific Corporation
BSX
$103.03
-$0.265-0.26%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 674.00M | 566.00M | 469.00M | 325.00M | 495.00M |
| Total Depreciation and Amortization | 325.00M | 348.00M | 306.00M | 311.00M | 304.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 220.00M | 218.00M | 61.00M | 386.00M | 108.00M |
| Change in Net Operating Assets | -678.00M | 324.00M | 166.00M | -209.00M | -743.00M |
| Cash from Operations | 541.00M | 1.46B | 1.00B | 813.00M | 164.00M |
| Capital Expenditure | -187.00M | -277.00M | -179.00M | -155.00M | -179.00M |
| Sale of Property, Plant, and Equipment | -- | 2.00M | 0.00 | 0.00 | -- |
| Cash Acquisitions | -239.00M | -3.42B | -1.13B | -48.00M | -47.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -74.00M | -11.00M | -121.00M | -68.00M | -59.00M |
| Cash from Investing | -500.00M | -3.70B | -1.43B | -271.00M | -285.00M |
| Total Debt Issued | 1.56B | 189.00M | 22.00M | 0.00 | 2.15B |
| Total Debt Repaid | -1.31B | 0.00 | 0.00 | 0.00 | -529.00M |
| Issuance of Common Stock | 115.00M | 28.00M | 96.00M | 26.00M | 80.00M |
| Repurchase of Common Stock | -- | -87.00M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -129.00M | 84.00M | -111.00M | -2.00M | -127.00M |
| Cash from Financing | 233.00M | 214.00M | 7.00M | 24.00M | 1.57B |
| Foreign Exchange rate Adjustments | 39.00M | -9.00M | 6.00M | -1.00M | -7.00M |
| Miscellaneous Cash Flow Adjustments | -- | -1.00M | -- | -- | -- |
| Net Change in Cash | 313.00M | -2.04B | -412.00M | 565.00M | 1.44B |